
The European Medicines Agency would use expedited procedures to approve new versions of the Covid-19 vaccines to address the omicron variant should the current ones prove insufficient to fight it off.
Emer Cooke, the agency’s director, told the European Parliament on Tuesday that regulatory approval could be completed in three to four months from when the companies are ready to move forward, but that testing is ongoing to evaluate how the variant responds to the current vaccines.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.